Investors Urged to Join Class Action Against Aardvark Therapeutics for Securities Fraud

Aardvark Therapeutics Securities Fraud Lawsuit

Overview
Investors in Aardvark Therapeutics, Inc. are being called to take action as significant allegations of fraud emerge amidst a recent class action lawsuit. Schall, Brown & Schwartz LLP (SBS), a recognized firm specializing in shareholder rights, is leading the charge against Aardvark for purported violations of the Securities Exchange Act of 1934.

Details of the Case
The lawsuit revolves around claims that Aardvark Therapeutics misrepresented vital information regarding its drug candidate, ARD-101. During the period following its initial public offering (IPO) on February 13, 2025, shareholders were misled about the safety and efficacy of ARD-101, which the company claimed had promising clinical and commercial potential. The lawsuit alleges that these misstatements caused investors to suffer substantial losses once the truth about the drug’s safety profile surfaced.

According to the complaint, Aardvark’s public statements throughout the IPO period were not only false but also materially misleading, causing serious repercussions for those who invested in Aardvark, especially after the company’s stock underperformed following the revelation of these misleading claims.

Who Should Get Involved?
Aardvark investors who acquired shares during the mentioned class period are being urged to contact SBS for potential lead plaintiff appointments. Notably, becoming a lead plaintiff is not a prerequisite for recovery, which means all affected shareholders can be part of the lawsuit regardless of their participation in this specific role.

Key Dates

- Class Period: From February 13, 2025, to May 14, 2026.
- Deadline for Lead Plaintiff Appointments: October 13, 2026.

Shareholders who felt significant damages from their investment in Aardvark are strongly encouraged to reach out to SBS before the deadline. Those interested can contact Brian Schall or David Schwartz at their Los Angeles office or visit the firm's official website for further assistance.

Why Choose SBS?
Schall, Brown & Schwartz LLP has built a reputable portfolio by representing investors globally who have suffered losses due to securities fraud. With a dedicated team that includes founders Brian Schall, Andrew Brown, and David Schwartz, the firm has made a commitment to advocate vigorously on behalf of investors’ rights. The firm ensures that every claim is handled with care and that all clients are accurately guided through the complex legal landscape of shareholder litigation.

Final Notes
Interested investors are encouraged to take action swiftly, as the class has yet to be certified. Time is of the essence; remaining an absent class member may limit recovery options later. For more information on participating in this lawsuit or understanding your rights as an investor, contact SBS today.

For additional inquiries, reach out to SBS at their Los Angeles office via phone or check their website. This lawsuit may also be classified under Attorney Advertising in certain jurisdictions according to legal standards.

Contact Information